In contrast, under pathologic conditions, such as muscular dystrophy, cancer associated cachexia and other diseases, in which the plasma levels of IL-6 significantly increase, the anabolic muscle activity of IL-6 might be impinged and prevails the persistent and systemic activity of IL-6, which promote muscle wasting with the possible participation of other mediators (33). This evidence concerns the gene IL6 and muscular dystrophy.